MedTrace Logo

HBV Reactivation in Immunocompromised Patients (REANT STUDY)

NCT07529171 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 490

Last updated 2026-08-04

No results posted yet for this study

Summary

Background/Objective: Comorbidities represent a critical risk factor in the prognosis of patients receiving immunosuppressive therapy. For patients with anti-HBc IgG positivity requiring Hepatitis B virus (HBV) prophylaxis, the long-term physiological impact of oral antivirals remains a concern. This study aims to prospectively monitor bone, renal, and metabolic dysfunctions associated with oral antiviral use and other systemic risk factors over a long-term period.

Methods: The REANT Cohort is designed as a 4-year, multicenter prospective study. The cohort will consist of patients initiated on HBV prophylaxis due to immunosuppressive treatment. Participants will undergo regular longitudinal assessments to evaluate bone mineral density, renal filtration and tubular functions, and metabolic profiles. The interplay between antiviral therapy, baseline comorbidities, and long-term organ dysfunction will be analyzed.

Conclusion: The findings from the REANT Cohort are expected to provide robust evidence regarding the safety of long-term HBV prophylaxis and assist in the development of monitoring guidelines for immunosuppressed patients with latent HBV infection.

Conditions

  • HBV

Interventions

DRUG

Antiviral

Patients who take all antivirals recommended in the guidelines will be evaluated in the same group.

Sponsors & Collaborators

  • SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY

    collaborator UNKNOWN

  • Yaşar Bayındır, MD

    lead OTHER

Principal Investigators

  • Yasar Bayındır, MD, Prof. · Guven Hospital

  • cigdem Mermutluoglu · Dicle University, Medical Faculty

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2026-08-30
Completion
2029-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07529171 on ClinicalTrials.gov